Revolution Medicines announced unprecedented Phase 3 results in pancreatic cancer
Arctic Aurora LifeScience holding, Revolution Medicines announced outstanding overall survival benefit in metastatic pancreatic cancer, one of the most lethal tumors.
Arctic Asset Management
Truly active approach
Arctic Asset Management is an independent Nordic Investment Manager, specialising in Nordic Equities, Nordic Fixed Income and Global Life Science.
We aim to create long-term value for our clients by carefully evaluating risk and reward in the markets.
Anyone can invest in the Arctic funds
Online Investment Platform
You don't need to be wealthy to start investing. As an online client, a sum of NOK 1,000 is enough to take the first step towards reaching your long-term financial goal.
Through our Online Investment Platform, anyone can invest in the Arctic funds. The portfolios are actively managed by our experienced investment teams.
Personal service for asset owners
Advisory Service
We offer advisory service to investment companies and institutional clients looking to invest in the Arctic funds.
Discretionary Mandates
We provide discretionary portfolio management for larger institutions and family offices.
Investment Strategies
Listen to our podcast!
"Arctic Midt i Måneden" is our mid-month podcast hosted by our CIO, Albert Collett. He invites fund managers and other selected guests to discuss market events, industries and sectors, and investment strategies - among other topics.
Latest News
Arctic Asset Management - Arctic Asset Management - Markedskommentar mars 2026
Markedene i mars ble påvirket av krigen i Iran som har spredt seg til store deler av Midtøsten og skapt betydelige globale ringvirkninger. Etter at USA og Israel angrep Iran på den siste dagen i februar, har regionen vært preget av krigshandlinger, med påfølgende avbrudd i råvareproduksjon og forsyningskjeder som har gitt økt markedsvolatilitet.
Arctic Asset Management - No slowing down of Biotech M&A: Soleno to be acquired by Neurocrine
On April 6, Arctic Aurora LifeScience holdings Soleno Therapeutics and Neurocrine Biosciences announced an agreement in which the mid-cap commercial biotech Neurocrine acquires Soleno for USD 2.9 billion or USD 53 per share - a 34% premium over the last closing price.
Arctic Asset Management - Apellis to be acquired by Biogen for 140% premium
On March 31, Arctic Aurora LifeScience portfolio company Apellis Pharmaceuticals announced that the company had agreed to be acquired by Biogen for an upfront cash consideration of USD 5.6 billion, representing a 140% premium on the latest closing price.
Arctic Asset Management - Arctic Midt i Måneden - Global uro, energisjokk og markedsmuligheter
Geopolitisk uro, stigende energipriser og økt markedsvolatilitet preger finansmarkedene i mars. Hva betyr dette for renter, aksjer og investorers posisjonering fremover? I denne episoden av Arctic Midt i Måneden diskuterer Albert Collett sammen med Cathrine Foyn, Tone Varmann og Alexander Larstedt Lager hvordan krig og usikkerhet påvirker markedene – og hvor mulighetene kan ligge i en urolig tid.
Arctic Asset Management - Unlocking Alpha in Biotech Through Active Selection
Yesterday, two companies in the Arctic Aurora LifeScience portfolio reported positive clinical data, which was rewarded by the market. Clinical execution and identifying companies with differentiated drug candidates yields excess returns, as demonstrated by Xenon's share price, which appreciated by close to 50% on positive data, and Dianthus, which appreciated by 21%.
Would you like to sign up for our newsletter?
